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Past genome-wide association studies (GWAS) involving in-
dividuals with AIDS have mainly identiﬁed associations in
theHLA region.Using the latest software,we imputed 7million
single-nucleotide polymorphisms (SNPs)/indels of the 1000
Genomes Project from the GWAS-determined genotypes of
individuals in the Genomics of Resistance to Immunodeﬁ-
ciency Virus AIDS nonprogression cohort and compared
them with those of control cohorts. The strongest signals
were in MICA, the gene encoding major histocompatibility
class I polypeptide-related sequence A (P = 3.31 × 10−12),
with a particular exonic deletion (P = 1.59 × 10−8) in full
linkage disequilibrium with the reference HCP5 rs2395029
SNP. Haplotype analysis also revealed an additive effect be-
tween HLA-C, HLA-B, and MICA variants. These data sug-
gest a role for MICA in progression and elite control of
human immunodeﬁciency virus type 1 infection.
Keywords. AIDS; elite control; GWAS; HIV-1; indel;
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More than 15 genome-wide association studies (GWAS) have
been published regarding AIDS progression [1]. They have
mainly pointed to associations in the HLA region of chromo-
some 6, involving candidate functional variants in the HLA-B
groove [2, 3] and the HLA-C region [4]. Our group has also
performed a GWAS using the Illumina 317K beadchip on the
Genomics of Resistance to Immunodeﬁciency Virus (GRIV)
cohort, the largest cohort of nonprogressor patients in theworld,
and we also identiﬁed the HCP5 rs2395029 single-nucleotide
polymorphism (SNP) corresponding to HLA-B57*01 [3]. All
of these past GWAS relied on DNA chips that covered only a
subset of genomic SNPs (up to 2.5 million for the latest Illumi-
na chips) but did not address important markers, such as indels.
In the present study, we computationally reanalyzed the geno-
typic data found in the GRIV cohort by means of Shape-IT and
IMPUTE 2 software [5, 6], exploiting the 40 million markers
(SNPs and indels) from the recently released 1000 Genomes
Phase I integrated variant set [7].
METHODS
Samples
The GRIV Cohort
The GRIV cohort was established in 1995 with white individu-
als of European descent living in France to identify host genes
associated with nonprogression to AIDS. Nonprogressors were
characterized as individuals who had had asymptomatic HIV
type 1 infection for >8 years, had not received treatment, and
had a CD4+ T-cell count of >500/mm3. DNA was obtained
from fresh peripheral blood mononuclear cells or from Epstein-
Barr virus–transformed cell lines. All patients provided written
informed consent before enrollment in the GRIV study.
The nonprogressor group (n = 266) was composed of 197
males and 69 females aged 19–62 years at the time of study in-
clusion. The viral load (plasma HIV RNA concentration) at
inclusion could be assessed for 248 individuals and allowed us
to deﬁne a group of elite controllers: 49 had a viral load of <100
copies/mL. For haplotype analysis, we distinguished the elite
controllers from the remaining nonprogressors, hereafter re-
ferred to as “nonelite nonprogressors” (n = 217).
The DESIR Control Group
This control group has been previously described by Le Clerc
et al [8] and comprised 694 nonobese, normoglycemic, HIV-
1–seronegative French participants from the DESIR trial. A
total of 281 individuals were male, and 413 were female, and
ages ranged from 30 to 64 years. All patients signed an informed
consent before enrollment in the genetic association study.
Additional Control Groups
In addition to the DESIR genotype data, we also used the geno-
types from individuals in the control cohort Supplémentation en
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Vitamines et Minéraux Antioxydants (SU.VI.MAX; n = 1352)
to conﬁrm the allelic frequencies of the main SNPs identiﬁed
in our case-control study. This control cohort of seronegative
subjects was previously described by Limou et al [3].
We also used the rapid progressors from the GRIV cohort
(n = 84) and the seroconverters from the ACS cohort (n = 404)
as supplementary control groups, to ensure that the association
results were not linked to infection. These 2 latter cohorts have
been described and reviewed by Limou et al [1].
Genotyping and Quality Control
Specimens from the GRIV nonprogressors and the control
groups were genotyped with the Illumina Inﬁnium II Human-
Hap300 BeadChips (Illumina, San Diego, CA). The methods
and quality controls were described by Le Clerc et al [8] and
Limou et al [3].
SNP Imputation
For each population, we started from the original genotypes ob-
tained by chips [1].Our pipeline worked with a prephasing step,
using Shape-IT [5], followed by imputation using IMPUTE2
[6]. This pipeline has been shown to be optimal [6]. To improve
accuracy and keep a reasonable number of subjects in each
group, some groups were prephased together, as follows: GRIV
nonprogressors and rapid progressors together with the DESIR
controls (n = 1044), the SU.VI.MAX controls (n = 1352), the
ACS controls (n = 404). SNP genotypes were imputed using
the 1000 Genomes Phase I integrated variant set [7] (with
SNPs and indels) as the reference panel. Only the variants im-
puted with high reliability (imputation quality score P > .8 [9])
were retained (n = 7 172 846).
Haplotypes
Haplotypes were computed with the Shape-IT software [5] for
the following 3 SNPs: the reference SNP rs9264942, corre-
sponding to HLA-C; the reference SNP rs2395029, correspond-
ing to the HCP5/HLA-B*5701/MICA*017 variant; and the SNP
rs112243036, corresponding to the strongest association found
in MICA (the gene encoding major histocompatibility class I
polypeptide-related sequence A) by the present study. The hap-
lotypes were computed after grouping together the controls, the
elite controllers, and the nonelite nonprogressors, and they were
then extracted separately for each subpopulation.
Statistical Analysis
The approximately 7 million reliably imputed polymorphisms
were compared between the nonprogressor group (n = 266)
and the DESIR control group (n = 694). For each SNP, pheno-
type was regressed on genotype dose by logistic regression with
the SNPtest software [9] in the additive mode, taking into
account stratiﬁcation by adding the 2 ﬁrst Eigenstrat PC axes
as covariates. For haplotype analysis, we compared the group
of elite controllers (n = 49) and nonelite nonprogressors
(n = 217) with the control group (n = 694) using the Fisher
exact test.
RESULTS AND DISCUSSION
After imputation based on the 317 000 SNPs initially genotyped
in the 266 GRIV nonprogressor cohort and the 694 DESIR con-
trols, we obtained reliable genotypes for 7 million variants. We
compared the nonprogressors from the GRIV cohort to the
DESIR controls (all of whom were white individuals) with re-
spect to these 7 million variants and found 55 signals passing
genome-wide signiﬁcance (P < 5 × 10−8) in the chromosome 6
HLA region only, in agreement with the previous GWAS on
HIV outcomes. Of those, 48 are in high linkage disequilibrium
(r2 > .8) with the previously described HCP5 rs2395029 SNP
(the tagSNP for the allele HLA-B*5701). A majority of those
SNPs/indels are located within the HLA-B and MICA genes
(Figure 1A), with the most signiﬁcant P values (up to
3.31 × 10−12) observed for the MICA gene, compared with
3 × 10−9 for the HLA-B SNPs (Supplementary Table 1). Our
strongest signal (P = 3.31 × 10−12) corresponded to the MICA
intronic rs112243036 SNP already identiﬁed for viral control
by the International HIV Controllers Study [2]. Whereas the
function of the HLA-B association has been extensively investi-
gated, the MICA association has not. We also looked at the best
SNP frequencies in several additional cohorts (rapid progressors
from the GRIV cohort, seroconverters from the ACS cohort,
and seronegative controls from the SU.VI.MAX cohort) and
found them to be similar to those in the DESIR cohort (Supple-
mentary Table 2), conﬁrming that the associations observed
were indeed linked with nonprogression to AIDS and not
with susceptibility to HIV infection.
As shown in Supplementary Table 1, among the 55 signals
passing the Bonferroni threshold, 48 are located close to or within
a gene (ie, near the 3′ or 5′ regions, in introns, in exons, or in the
3′ untranslated region), the location and the genetic context of
the identiﬁed SNPs are shown in Figure 1A. Among the 4 exonic
variants, the most remarkable was the deletion rs199503730
(P = 1.59 × 10−8) in the MICA gene, whose functional impact is
likely to be more dramatic than the impact of the 2 nonsynony-
mous mutations (Supplementary Table 1). Indeed, the deletion
induces a reading frameshift located just before the transmem-
brane section of the MICA protein, leading to a variation of
the protein sequence and a longer hydrophobic region in the
transmembrane region (Figure 1B). This deletion is carried
only by the 2 alleles MICA*017 and MICA*015 [10]. Since
MICA*015 is extremely rare in the European population and
has always been observed in associated withHLA-B*45 [11], rath-
er than with the HLA-B*5701 allele found in our patients, we will
only discuss MICA*017 in the remainder of this article. Interest-
ingly, in our cohort, the MICA deletion (and, thus, MICA*017)
was in perfect linkage disequilibrium with the reference HCP5
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rs2395029 SNP and with HLA-B*5701 (r2 = 1). Since it is in the
vicinity of the putative cleavage zone of soluble MICA [12], this
deletion may impact the shedding of MICA (Figure 1B), thus
providing an additional functional explanation for the well-
known genetic association of the rs2395029 SNP.
In addition to HLA-B*5701, previous works had also unrav-
eled associations between HLA-C variant rs9264942 and poten-
tial biological explanations of viral control and nonprogression
[1, 3]. To see whether our MICA associations could shed new
light on these associations, we evaluated the haplotypes of the
most signiﬁcant variants of HLA-C, HLA-B and MICA in con-
trols (n = 694), nonelite nonprogressors (n = 217), and elite
controllers (n = 49): rs9264942, for HLA-C [1]; rs2395029, for
HLA-B*5701 [1] (in full linkage disequilibrium with the
rs199503730 deletion corresponding to MICA*017); and
rs112243036, for MICA (the strongest signal identiﬁed by our
study and previously mentioned by Pereyra et al [2]; Supple-
mentary Table 1). Analysis of the haplotypes allowed us to
draw some conclusions about the interplay between rs9264942,
rs2395029, and rs112243036 (Table 1). In contrast to what has
been described in the literature [2], the frequency of haplotype
CTG (odds ratio [OR ], 1.00; 95% conﬁdence interval [CI],
0.62–1.60; P = 1) suggested that the HLA-C rs9264942 C allele
was not effective unless combined with the HLA-B*5701/
MICA*017 rs2395029 G allele and/or the MICA rs112243036
A allele for viral control and nonprogression (haplotypes CGG
and CTA, respectively; Table 1). A major signal was also observed
for haplotype CGA (OR, ∞; 95% CI, 6.03–∞; P = 2.65 × 10−4)
Figure 1. A, Genetic map of the HLA region. Only the single-nucleotide polymorphisms found signiﬁcant after imputation in this study are represented.
The exonic variants are in red, the other variants are in black, and the indels are underlined. The black boxes are the exons, the gray boxes represent the 3′
and 5′ untranslated regions, and the striped boxes in black and white represent pseudogenes. The start and stop codons for each gene are black arrows in
the direction of the transcription. The scale is given in kilobases (kb). B, Representation of the major histocompatibility class I polypeptide-related sequence
A (MICA) proteins coded by the alleles MICA*001 (the reference MICA allele), MICA*008 (the most frequent allele in Europeans), and MICA*017 (corre-
sponding to the deletion rs199503730). The sequence variations before the transmembrane region, which corresponds to the putative cleavage site involved
in the shedding of MICA, are detailed. The MICA*017 sequence is unique among the MICA alleles of the European population.
1948 • JID 2014:210 (15 December) • BRIEF REPORT
when comparing elite controllers to controls, whereas the signal
became weaker when comparing nonelite nonprogressors to
controls, suggesting that these 3 SNPs were more important
for viral control than for the nonprogression phenotype. The
frequency of this latter haplotype was conﬁrmed independently
in other cohorts of elite controllers (C. Coulonges, personal
communication). We used logistic regression to determine
whether the combined effect of the 3 SNPs was additive or syn-
ergistic by comparing the 2 models by means of analysis of var-
iance. The effect appeared to be additive, as the improvement
brought about by the inclusion of the interaction between all
3 SNPs was not signiﬁcant (P = .10).
Overall, this novel analysis of imputed SNPs/indels suggests a
prominent role for variants of the MICA protein with multiple
associations found in this gene.
First, the strongest associations were observed for MICA var-
iants. MICA encodes a protein that functions as a ligand for
NKG2D, which is present on CD8+ α/β T cells, γ/δ T cells,
and natural killer (NK) cells [13]. The engagement of NKG2D
activates cytolytic responses of γ/δ T cells and NK cells against
infected cells and tumor cells [13].
Second, the MICA deletion rs199503730, which corresponds
to the alleles MICA*017 and HLA-B*5701 in the white popula-
tion, was consistently overrepresented among elite controllers in
our study (15.32%), as well as those in other published studies
(13.9% in the study by Pereyra et al [2] and 16.7% in the study
by Dalmasso et al [14]), compared with controls. ThisMICA de-
letion is located near the putative cleavage site of MICA, ahead
of the transmembrane region [12], and could thus lead to a
lower level of soluble MICA by preventing shedding (Figure 1B).
Recent studies have measured higher levels of soluble MICA for
individuals with chronic HIV infection, compared with healthy
controls and HIV controllers [15], which could be important
since soluble MICA interacts with the NKG2D receptor and
impairs the cytotoxicity of NK cells during HIV infection [15].
This shedding would not occur in the HLA-B*5701/MICA*017
elite controllers: the exceptional strength of the well-known
HCP5 rs2395029 association with nonprogression and viral
load control could thus be explained by the additive functional
effects of the HLA-B*5701 and MICA*017 variants.
Third, the haplotype analysis of the elite controller and non-
elite nonprogressor groups revealed a combined effect of the well-
knownHLAB*5701/MICA*017 allele,HLA-C rs9264942-C allele,
and the strongest MICA signal, rs112243036 A allele. This latter
effect could be explained by the combined action of MICA on
innate immunity and of HLA on adaptive immunity.
The use of imputation has unraveled new signals in theMICA
gene with a putative biological explanation, and our haplotype
analysis revealed the combined effects of HLA-C, HLA-B, and
MICA variants in the GRIV cohort. All of the data suggest a
role of MICA in disease progression and elite control and un-
derline the importance of the interaction of several components
of the immune system during AIDS progression. These results
provide new clues for the mechanisms of elite control and non-
progression of HIV infection and will require conﬁrmation by
functional investigations.
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Table 1. Analysis of Haplotype Associations for the 3 Reference Single-Nucleotide Polymorphisms (SNPs)
Haplotype Allelic Frequency (%) Elite vs Control NPNE vs Controls
HLA-C
HLA-
B*5701 MICA
Control
(n = 694)
Elite
(n = 49)
NENP
(n = 217) P Value OR (95% CI) P Value OR (95% CI)
T T G 54.90 25.00 39.90 1.05 × 10−8 0.27 (.16–.44) 6.87 × 10−8 0.54 (.43–.68)
C T G 31.30 31.20 30.30 1 1.00 (.62–1.60) 7.65 × 10−1 0.96 (.75–1.22)
C T A 6.20 18.70 15.00 5.90 × 10−5 3.47 (1.87–6.19) 5.98 × 10−8 2.66 (1.85–3.80)
T T A 4.80 9.40 6.80 5.46 × 10−2 2.06 (.87–4.34) 1.06 × 10−1 1.45 (.89–2.33)
C G A 0.00 3.10 0.20 2.65 × 10−4 ∞ (6.03–∞) 2.35 × 10−1 ∞ (.08–∞)
T G G 0.70 4.20 2.30 1.00 × 10−2 5.95 (1.34–21.15) 1.31 × 10−2 3.29 (1.22–8.88)
C G G 2.30 8.30 5.20 3.20 × 10−3 3.83 (1.48–8.82) 4.94 × 10−3 2.29 (1.26–4.13)
T G A 0.00 0.00 0.20 NaN NaN 2.36 × 10−1 ∞ (.08–∞)
rs9264942 was analyzed for HLA-C, rs2395029 was analyzed for HLA-B*5701 (in full linkage disequilibrium with rs199503730 deletion corresponding to
MICA*017), and rs112243036 corresponded to the best SNP located in MICA. The linkage disequilibrium between the 3 SNPs is weak, with r2 vales of <0.1
between each SNP for each population. The minor alleles of interest for each variant are highlighted in bold.
Abbreviations: CI, confidence interval; Elite, elite controllers; NaN, not a number; NENP, nonelite nonprogressors; OR, odd ratio.
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